Original reporting and analysis on the stories shaping biotech.
OpenAI just dropped GPT-Rosalind, a purpose-built AI for drug discovery that already outperforms 95% of human experts on certain biology tasks. Amgen, Moderna, and Novo Nordisk are already on board, but can a language model actually make drugs get to patients faster?
The FDA just reclassified non-invasive bone growth stimulators from Class III to Class II, slashing the regulatory barrier that protected incumbent players for nearly 50 years. A $2 billion market is about to get a lot more crowded.
Aligos Therapeutics licensed its hepatitis B drug to a Chinese partner in a deal worth up to $445 million. With a market cap under $50 million and cash running low, did the company sell a goldmine or pull off a masterclass in survival strategy?
AKT inhibitors have broken Big Pharma's heart for years, but Terremoto just raised $108M to try again with a radically different approach. With $358M in total funding and a selective targeting strategy, the startup is betting it can crack one of oncology's most frustrating puzzles.
A two-year-old company you've probably never heard of just pulled off the largest biotech IPO in history, raising $625 million on a bet that the obesity drug market is big enough for more than just Novo and Lilly. The money, the drugs, and the risks: all of it.
Revolution Medicines just dropped Phase 3 data showing its pancreatic cancer drug nearly doubled survival over chemo, a result almost unheard of in oncology's deadliest cancer. Now Merck reportedly wants to buy the whole company for up to $32 billion.
A sweeping new review of 17 clinical trials says anti-amyloid Alzheimer's drugs provide no meaningful benefit to patients, directly challenging the multibillion-dollar bet behind lecanemab and donanemab. The Alzheimer's establishment is pushing back hard, but the cracks in the amyloid hypothesis are getting harder to ignore.
A brand-new startup just walked out the door with five autoimmune drug programs from Bristol Myers Squibb and $300 million in backing. Beeline Medicines might be the best-funded biotech debut of the year, and its first big data readout is already on the clock.
MeiraGTx paid $25 million to buy back a gene therapy that J&J acquired for up to $415 million, after the program's Phase 3 trial missed its primary endpoint. Now the company is racing to file for approval anyway, betting that J&J walked away too soon.
Storm Therapeutics just raised $56 million and dosed the first patient in a Phase 2 sarcoma trial, all for a drug targeting an enzyme most people have never heard of. It's the biggest clinical milestone yet for epitranscriptomics, a therapeutic field that literally didn't exist a decade ago.
For decades, patients with a rare kidney disease called FSGS had zero approved treatments. Travere Therapeutics just changed that with the first-ever FDA-approved therapy, and Wall Street thinks it could be worth $2 billion.
Bain Capital just launched a $300 million biotech startup built entirely from Bristol Myers Squibb's castoff drugs. The CEO? The same guy who turned a Pfizer spinout into a $3.9 billion acquisition. Meet Beeline Medicines.
Novartis CEO Vas Narasimhan just became the first Big Pharma chief to join the board of a frontier AI company, landing a seat at Anthropic. It's a signal that pharma and AI are no longer flirting; they're moving in together.
The FDA approved Lilly's obesity pill Foundayo at record speed, then demanded five years of liver monitoring despite clean trial data. No liver problems showed up in trials, but the agency wants proof that stays true when millions start popping the pill.
A daily pill from Revolution Medicines nearly doubled survival in advanced pancreatic cancer patients compared to chemo, cracking a target that scientists called 'undruggable' for 40 years. The results were so strong the trial was stopped early, and even a former U.S. senator enrolled.
Spain is dropping $200 million on a government-backed biotech VC fund anchored in Boston, the first time a European country has seeded a venture fund on U.S. soil. It's a bold play to close Europe's biotech funding gap, and it might reshape how countries compete for life sciences talent.
Early-stage biotech funding cratered 38% in Q1 2026, and the startups that could produce tomorrow's cures are running out of cash. The IPO market is flush, but only for companies that already have the data investors demand.
The FDA's advisory committee just rejected six popular peptides from the compounding pharmacy playbook, and it's part of a much bigger crackdown targeting GLP-1 copycats and unapproved wellness peptides. The $50 billion peptide market will never look the same.
Novo Nordisk and OpenAI just struck a deal to embed AI across drug discovery, manufacturing, and operations, with full integration by year's end. It's the biggest signal yet that pharma's AI era has gone from PowerPoint fantasy to boardroom reality.
Gene therapies can cost millions per patient, and most never achieve commercial success. Ocugen's CEO thinks the industry is solving the wrong problem, and he's betting the company on manufacturing scale and affordable pricing over scientific novelty.
Astellas Pharma is shuttering its Seattle stem cell unit and cutting 55 jobs, eight years after paying $102.5 million for the technology. The move raises fresh questions about whether regenerative medicine can ever close the gap between scientific promise and commercial reality.
Click Therapeutics raised $50 million and then cut 27% of its staff in the same week. The company is betting it can succeed where Pear Therapeutics spectacularly failed: turning a prescription app into a real commercial product.
Join thousands of biotech professionals who start their day with our free, daily briefing.